FDA AI Warning Letter Raises the Bar for Model Validation

By Priya Raman

In April 2026, the FDA issued its first cGMP warning letter with a dedicated section on inappropriate AI use: Purolea Cosmetics Lab, case 722591, dated 2 April and updated 14 April. That enforcement example makes internal AI policies a potential line of inspection evidence for companies subject to cGMP.

The regulatory setting extends beyond model performance. Earlier in 2026, the FDA and European Medicines Agency released 10 joint guiding principles for AI in drug development. The European Commission’s proposed GMP Annex 22 on AI remained unfinalized, while the United Kingdom accepted all 44 recommendations of its National Commission into the Regulation of AI in Health care in October 2026.

The FDA principles carry a 14 January 2026 update date, while the UK commission’s recommendations are dated 10 September 2026.

What does the FDA letter change for AI validation?

On PharmTech’s AI Pulse Check, Richard Jaenisch brought back a signal from the International Society for Pharmaceutical Engineering Annual Meeting: regulators will test pharmaceutical companies against their own internal AI policies. The claim came from Jaenisch’s meeting account, not a published survey or a regulator’s formal enforcement forecast.

The episode disclosed no funding source or panel affiliations and supplied no inspection dataset or sampling frame. Its regulatory forecast therefore remains panel interpretation rather than measured inspector behavior.

Florin Muraru said: “Regulators don't read your playbook. They test it and look at who owns a process.” He called the April FDA letter the first such test and expected more.

Jaenisch said inspectors will examine policy execution, alignment with current standards and consistency. A vague policy can help only until a division operates outside its boundaries, and every policy must link to other regulatory guidance.

Where should teams begin with AI?

Gourav Pandey said: “You don't need a perfect policy or a fully validated model on day one. You need something you can explain, have evidence for, and follow.”

He identified teams’ tendency to start with fully autonomous, high-impact deployments as the main implementation stall. His practical sequence was to map workflows already approved in standard operating procedures and defensible in audits, then find where AI can shorten the work without displacing the existing review decision.

In regulatory writing, AI could dig through a 600-page batch record to pull a specification or test value while the existing review workflow drives the decision. The panel offered this as a workflow example, not a measured accuracy result, and disclosed no time saving, error rate or implementation cost.

What should an inspection-ready control set contain?

Muraru advised teams to inventory every AI use, including tools running through personal accounts. He identified shadow AI as the largest risk, although the episode gave no incident rate or supporting sample. For a first use, he favored low-risk cases in which a person checks every output and the company records the model and the person who signs.

That design should answer inspectors’ two questions: what is the tool for, and who is accountable? In Europe, the EU AI Act makes staff AI literacy training mandatory. Jaenisch argued that company-specific training should extend beyond universal instruction on what not to do: internal experts should define what users may do, because AI could also write bad deviations faster.

Why does model ownership matter to budget and validation?

Jaenisch said some organizations have not slowed because they are spending on chips and systems for deployments that are almost on-premises. The panel gave no capital figure or deployment scale and said it can take years to understand what an investment of that size can do. This is a strategic argument, not a cost-benefit result.

Pandey said an organization that owns a model has greater control and can validate and defend it more readily than a user of frontier models that change weekly. Ownership, on this account, changes both the operating burden and the evidence available to an inspector; the panel did not quantify either effect.

Muraru described the UK as moving from one-time AI approval toward oversight across a system’s life, referencing the FDA’s generative AI paper. He said a policy must define monitoring, change control and the point at which an update needs a fresh look. Regulators also use AI, he added, raising the question of who validates the regulators’ systems.

What should the expected December playbook settle?

Muraru said the playbook should establish proportionality: which uses require full validation and which can operate with lighter controls. Large companies can map parallel documents, he said, while smaller organizations may struggle to know which requirements apply to them.

Pandey called for predetermined change-control plans that define when a provider model update or a change to the company’s own harness is substantial enough to trigger notification, suspension or revalidation. He also placed accountability for the model, stack and architecture with the company rather than the provider. No threshold values were proposed.

Jaenisch asked for authorship rules at a granular level, separating AI contributions from human contributions. He also proposed a Model Context Protocol backend so staff can connect a compliance playbook to tools they already use. The panel did not identify the publisher, final content or approval path for the expected December guidance, leaving those operational details unresolved.

As the December playbook approaches, R&D and quality leaders should choose one low-risk, human-reviewed workflow, document model ownership and a revalidation trigger, and test the policy against the April FDA letter. The panel offers a control sequence, not proof that an owned model has passed inspection.